cohen youngs data science, inc.

7014 13th avenue
suite 202
brooklyn, new york 11228

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 26, 2014

NYS DOS ID#
4627149

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
UNITED STATES CORPORATION AGENTS, INC.
7014 13TH AVENUE
SUITE 202
BROOKLYN, NEW YORK, 11228

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - COHEN YOUNGS DATA SCIENCE, INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • 19th-Century Diary Suggests Slaves Are Buried in Brooklyn Lot
    By MICHAEL WILSON - Friday Aug 4, 2017

    A Gowanus farmer’s writings from 1828 to 1830 describe burying them on property that includes the proposed site of a prekindergarten.

    Source: NYT > Home Page
  • SUMMER FIRSTS | Brooklyn: Finding Alchemy and Art on a Coney Island Scary Ride
    By FRANCINE PROSE - Wednesday Aug 2, 2017

    For Francine Prose, an amusement-park trip as a young girl led to a ride on the Spook-a-Rama and later to a prized Diane Arbus photo of the same ride.

    Source: NYT > Home Page
  • A New Kind of Classroom: No Grades, No Failing, No Hurry
    By KYLE SPENCER - Friday Aug 11, 2017

    Mastery-based learning allows students to learn at their own pace.

    Source: NYT > Home Page
  • DataCamp Nabs $4M for Data Science Courses, Moves to NY
    By Jeff Engel - Thursday Jul 27, 2017

    Data scientists remain in high demand. But these days, many types of professionals can boost their career prospects if they have at least a basic level of “data literacy,” says Jonathan Cornelissen. That’s part of the reason why he says his online education company, DataCamp, has been growing over the past couple of years. DataCamp, […]

    Source: Xconomy New York
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York